Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
Conclusions: Results suggest that ocrelizumab has an efficacy superior to or comparable with all other currently approved DMTs across all endpoints analyzed, and a similar safety profile, indicating it offers a valuable package for the treatment of patients with RMS.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
More News: Avonex | Conferences | Databases & Libraries | Disability | European Medicines Agency (EMA) | Multiple Sclerosis | Rebif | Websites